Literature DB >> 21176016

Reduced-intensity conditioning for alternative donor hematopoietic stem cell transplantation in patients with dyskeratosis congenita.

Nobuhiro Nishio1, Yoshiyuki Takahashi, Haruhiko Ohashi, Sayoko Doisaki, Hideki Muramatsu, Asahito Hama, Akira Shimada, Hiroshi Yagasaki, Seiji Kojima.   

Abstract

DC is an inherited bone marrow failure syndrome mainly characterized by nail dystrophy, abnormal skin pigmentation, and oral leukoplakia. Bone marrow failure is the most common cause of death in patients with DC. Because previous results of HSCT with a myeloablative regimen were disappointing, we used a reduced-intensity conditioning regimen for two patients with classic DC, and one patient with cryptic DC who harbored the TERT mutation. Graft sources included two mismatched-related bone marrow (BM) donors and one unrelated BM donor. Successful engraftment was achieved with few regimen-related toxicities in all patients. They were alive 10, 66, and 72 months after transplantation, respectively. Long-term follow-up is crucial to determine the late effects of our conditioning regimen.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2010        PMID: 21176016     DOI: 10.1111/j.1399-3046.2010.01431.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  11 in total

1.  Reduced intensity conditioning regimen with fludarabine, cyclophosphamide, low dose TBI and alemtuzumab leading to successful unrelated umbilical cord stem cell engraftment and survival in two children with dyskeratosis congenita.

Authors:  M Brown; D Myers; N Shreve; R Rahmetullah; M Radhi
Journal:  Bone Marrow Transplant       Date:  2016-01-25       Impact factor: 5.483

2.  TCR αβ and CD19-depleted haploidentical stem cell transplant with reduced intensity conditioning for Hoyeraal-Hreidarsson syndrome with RTEL1 mutation.

Authors:  R Bhattacharyya; A M Tan; M Y Chan; S S Jamuar; R Foo; P Iyer
Journal:  Bone Marrow Transplant       Date:  2016-01-25       Impact factor: 5.483

Review 3.  Inherited bone marrow failure syndromes in 2012.

Authors:  Hirotoshi Sakaguchi; Koji Nakanishi; Seiji Kojima
Journal:  Int J Hematol       Date:  2012-12-28       Impact factor: 2.490

Review 4.  Allogeneic hematopoietic stem cell transplantation for inherited bone marrow failure syndromes.

Authors:  Jean-Hugues Dalle; Régis Peffault de Latour
Journal:  Int J Hematol       Date:  2016-02-12       Impact factor: 2.490

5.  Monitoring and treatment of MDS in genetically susceptible persons.

Authors:  Stella M Davies
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 6.  Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation.

Authors:  Andrew C Dietz; Parinda A Mehta; Adrianna Vlachos; Sharon A Savage; Dorine Bresters; Jakub Tolar; Farid Boulad; Jean Hugues Dalle; Carmem Bonfim; Josu de la Fuente; Christine N Duncan; K Scott Baker; Michael A Pulsipher; Jeffrey M Lipton; John E Wagner; Blanche P Alter
Journal:  Biol Blood Marrow Transplant       Date:  2017-01-20       Impact factor: 5.742

Review 7.  Recent advances in hematopoietic cell transplantation for inherited bone marrow failure syndromes.

Authors:  Hirotoshi Sakaguchi; Nao Yoshida
Journal:  Int J Hematol       Date:  2022-05-28       Impact factor: 2.490

8.  Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita.

Authors:  Shahinaz M Gadalla; Carmem Sales-Bonfim; Jeanette Carreras; Blanche P Alter; Joseph H Antin; Mouhab Ayas; Prasad Bodhi; Jeffrey Davis; Stella M Davies; Eric Deconinck; H Joachim Deeg; Reggie E Duerst; Anders Fasth; Ardeshir Ghavamzadeh; Neelam Giri; Frederick D Goldman; E Anders Kolb; Robert Krance; Joanne Kurtzberg; Wing H Leung; Alok Srivastava; Reuven Or; Carol M Richman; Philip S Rosenberg; Jose Sanchez de Toledo Codina; Shalini Shenoy; Gerard Socié; Jakub Tolar; Kirsten M Williams; Mary Eapen; Sharon A Savage
Journal:  Biol Blood Marrow Transplant       Date:  2013-06-08       Impact factor: 5.742

Review 9.  Evaluation and Management of Hematopoietic Failure in Dyskeratosis Congenita.

Authors:  Suneet Agarwal
Journal:  Hematol Oncol Clin North Am       Date:  2018-05-28       Impact factor: 3.722

10.  A Reduced-Intensity Conditioning Regimen for Patients with Dyskeratosis Congenita Undergoing Hematopoietic Stem Cell Transplantation.

Authors:  Adam S Nelson; Rebecca A Marsh; Kasiani C Myers; Stella M Davies; Sonata Jodele; Tracey A O'Brien; Parinda A Mehta
Journal:  Biol Blood Marrow Transplant       Date:  2016-02-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.